An observational study in Atrial Fibrillation (AF), Atrial Flutter and Supraventricular Tachycardias, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Heinrich-Heine University, Duesseldorf · Observational
This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.
This is a single-center observational registry including all patients treated with EPS, catheter ablation, or electrical cardioversion at the Department of Cardiology, Pneumology, and Angiology, University Hospital Düsseldorf. Retrospective data from 2011 onward and prospective data from 2015 onward are collected.
The registry systematically records demographic data, comorbidities, laboratory and imaging results, procedural details, and follow-up outcomes. Patients are routinely followed at 1, 3, 6, 12, and 24 months after the procedure. Additional follow-up may be performed by telephone interview with patients or referring physicians to improve data quality.
Primary endpoints focus on safety (peri- and postprocedural complications, late adverse events) and efficacy (recurrence of arrhythmias, need for repeat procedures, pacemaker implantation, or new medications). Secondary endpoints include hospitalization and all-cause mortality.
Participation does not alter routine diagnostic or therapeutic decisions, and no additional invasive procedures are performed. Data will be used for quality assurance and to improve understanding of prognostic factors, with the ultimate aim of optimizing future patient care.
4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with heart rhythm disorders
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periprocedural and postprocedural safety events
All cardiovascular adverse events or complications occurring during hospitalization and late complications after discharge related to EPS, ablation, or electrical cardioversion.
Time frame: Up to 24 months after procedure
Clinical efficacy outcomes
Procedural success, recurrence of arrhythmias or symptoms, and need for repeat EPS/cardioversion, additional medication, or device implantation (e.g., pacemaker).
Time frame: Up to 24 months after procedure
All-cause mortality
Death from any cause during follow-up.
Time frame: Up to 24 months after procedure
All-cause hospitalization
Any hospital admission for cardiovascular or non-cardiovascular reasons during follow-up
Time frame: Up to 24 months after procedure
Plan to share: No — not necessary as its a registry
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heinrich-Heine University, Duesseldorf →